Aziyo Biologics is a medical devices business based in the US. Aziyo Biologics shares (AZYO) are listed on the NASDAQ and all prices are listed in US Dollars. Aziyo Biologics employs 151 staff and has a trailing 12-month revenue of around $48.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.64 |
|---|---|
| 52-week range | $1.10 - $1.80 |
| 50-day moving average | $1.46 |
| 200-day moving average | $2.52 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.18 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.64 from 2023-11-08
| 1 week (2024-08-25) | N/A |
|---|---|
| 1 month (2024-08-01) | N/A |
| 3 months (2024-06-01) | N/A |
| 6 months (2024-03-01) | N/A |
| 1 year (2023-09-05) | 12.33% |
|---|---|
| 2 years (2022-09-02) | -76.57% |
| 3 years (2021-09-03) | 8.4 |
| 5 years (2019-09-01) | N/A |
| Revenue TTM | $48.4 million |
|---|---|
| Gross profit TTM | $19.2 million |
| Return on assets TTM | -28.75% |
| Return on equity TTM | -775.14% |
| Profit margin | -70.13% |
| Book value | $-1.36 |
| Market Capitalization | $24.2 million |
TTM: trailing 12 months
We're not expecting Aziyo Biologics to pay a dividend over the next 12 months.
Over the last 12 months, Aziyo Biologics's shares have ranged in value from as little as $1.1001 up to $1.7999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aziyo Biologics's is -0.0846. This would suggest that Aziyo Biologics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aziyo Biologics has bucked the trend.
To put Aziyo Biologics's beta into context you can compare it against those of similar companies.
Aziyo Biologics, Inc. , a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women's health, orthobiologics, cardiovascular, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.